ASF 1081Alternative Names: ASF-1081
Latest Information Update: 27 Mar 2006
At a glance
- Originator Astion Pharma A/S
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Clinical Phase Unknown Atopic dermatitis
Most Recent Events
- 27 Mar 2006 Clinical trials in Atopic dermatitis in Denmark (PO)